英国和爱尔兰社区获得性下呼吸道感染病原体耐药趋势(1999/2000至2018/2019)
BSAC呼吸监测计划分析了1999/00至2018/19年社区获得性下呼吸道感染患者中肺炎链球菌、流感嗜血杆菌和卡他莫拉菌的耐药趋势。耐药总体不常见,但流感嗜血杆菌产β-内酰胺酶比例约20%,卡他莫拉菌>90%,肺炎链球菌青霉素完全耐药仅0.11%。
要点
- 肺炎链球菌青霉素完全耐药率极低(0.11%),co-amoxiclav对流感嗜血杆菌和卡他莫拉菌抑制率>97.8%。
- 流感嗜血杆菌产β-内酰胺酶约20%,卡他莫拉菌>90%,且出现β-内酰胺酶非依赖的amoxicillin/co-amoxiclav耐药。
- 头孢菌素对β-内酰胺酶阳性与阴性卡他莫拉菌MIC差异显著(ceftaroline达512倍),临床意义不明。
核心结论
- CA-LRTI仍高度可治疗,但肺炎链球菌耐药相关血清型更替及流感嗜血杆菌amoxicillin耐药性质变化值得关注。
研究设计与样本
- BSAC呼吸监测计划,1999/00至2018/19年每年10月开始收集社区获得性下呼吸道感染患者分离株,采用琼脂稀释法测MIC, nitrocefin检测β-内酰胺酶,肺炎链球菌血清分型用经典方法或WGS。
主要发现
- 肺炎链球菌对青霉素完全耐药仅0.11%(12/10881);co-amoxiclav抑制97.8%的13526株流感嗜血杆菌和>99.9%的6309株卡他莫拉菌。
- 头孢噻肟在折点处抑制>99%所有分离株;相关氟喹诺酮类在测试年份亦如此。
- 四环素抑制>98%的流感嗜血杆菌和卡他莫拉菌,以及85%的肺炎链球菌。
- 流感嗜血杆菌产β-内酰胺酶比例从2012/13年起约20%;卡他莫拉菌始终>90%。
- 2012/13年起,β-内酰胺酶非依赖的amoxicillin/co-amoxiclav耐药流感嗜血杆菌比例扩大,且β-内酰胺酶阳性流感嗜血杆菌中高水平amoxicillin耐药(MIC>64 mg/L)增加。
关键数值与推荐
- 肺炎链球菌青霉素完全耐药率0.11%(12/10881)。
- co-amoxiclav对流感嗜血杆菌抑制率97.8%(13526株),对卡他莫拉菌>99.9%(6309株)。
- 头孢噻肟在折点处抑制>99%所有分离株。
- 四环素对流感嗜血杆菌和卡他莫拉菌抑制>98%,对肺炎链球菌85%。
- 流感嗜血杆菌产β-内酰胺酶约20%(2012/13年起),卡他莫拉菌>90%。
临床怎么用
- CA-LRTI经验性治疗仍可选择co-amoxiclav等,但需关注流感嗜血杆菌amoxicillin耐药新机制及卡他莫拉菌头孢菌素MIC差异的潜在影响。
局限性
- 卡他莫拉菌β-内酰胺酶相关头孢菌素MIC差异的临床意义尚不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The BSAC Respiratory Surveillance Programme examined resistance trends among Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired lower respiratory tract infection (CA-LRTI). METHODS: Quotas of isolates were sought per collecting site from 1999/00 to 2018/19; an annual October start date captured winter infection peaks within single years. MIC testing was by BSAC agar dilution. β-Lactamase detection with nitrocefin and pneumococcal serotyping by classical methods or WGS. RESULTS: Resistances were uncommon, except that β-lactamases occurred in c. 20% of H. influenzae from 2012/13 following earlier rises, and in >90% of M. catarrhalis throughout. Only 0.11% (12/10881) of S. pneumoniae were fully resistant to penicillin; co-amoxiclav inhibited 97.8% of 13526 H. influenzae and >99.9% of 6309 M. catarrhalis isolates. Cefotaxime inhibited >99% of all isolates at breakpoint, as did relevant fluoroquinolones in the fewer years tested. Tetracycline inhibited >98% of H. influenzae and M. catarrhalis and 85% of S. pneumoniae. Significant shifts were: (i) fluctuating resistances to tetracyclines, macrolides and penicillin in pneumococci, reflecting serotype replacements; (ii) expansion, from 2012/13, in the proportion of H. influenzae with β-lactamase-independent amoxicillin/co-amoxiclav resistance; and (iii) increasing high-level amoxicillin resistance (MIC > 64 mg/L) among β-lactamase-positive H. influenzae. MIC differentials were seen for cephalosporins between β-lactamase-positive and β-lactamase-negative M. catarrhalis, greatest (512-fold) for ceftaroline. CONCLUSIONS: CA-LRTI remains eminently treatable, yet shifts are occurring in the serotypes of S. pneumoniae most associated with resistance and in the nature of amoxicillin resistance in H. influenzae. β-Lactamase-related cephalosporin MIC differentials for M. catarrhalis are striking but their clinical significance remains uncertain.
引用
- Reynolds R, Felmingham D, Mushtaq S, et al. Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019. J Antimicrob Chemother. 2025. PMID: 41140274. doi:10.1093/jac/dkaf252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。